Organization (Other)
Hennepin Healthcare Research Institute
ClinicalTrials.gov lists Hennepin Healthcare Research Institute as lead sponsor of 69 trials. It has 21 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Hennepin Healthcare Research Institute: 69 lead-sponsored trials and 1 legal-entity registration.
Disease areas (68)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Substance-Related Disorders | 12 |
| Diabetes Mellitus | 8 |
| Opioid-Related Disorders | 8 |
| Pain | 7 |
| Acute Coronary Syndrome | 6 |
Showing 5 of 68 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 9 |
| 2020 | 4 |
| 2019 | 3 |
| 2018 | 5 |
| 2017 | 7 |
| 2016 | 9 |
Showing 10 of 23 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (21)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| PROPOFOL | 5 |
| (R,S)-ketamine (Pilot I) | 3 |
| Alfentanil | 2 |
| Aspirin | 2 |
| Conjugate Pneumococcal Vaccine 20 (PCV20) | 1 |
Showing 5 of 21 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 30% hit target (n=23) | 35% on time (n=26) |
Journals published in (129)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Annals of emergency medicine | 9 |
| Academic emergency medicine : official journal of the Society for Academic Emergency Medicine | 7 |
| The American journal of emergency medicine | 6 |
| Addiction science & clinical practice | 5 |
| Prehospital emergency care | 5 |
Showing 5 of 129 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2 | 2 | 2024-08-27 |
Financing and grant events (95)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-30 | NIH grant | 2,791,999 | Reporter |
| 2025-09-17 | NIH grant | 504,011 | Reporter |
| 2025-08-19 | NIH grant | 180,494 | Reporter |
| 2025-07-31 | NIH grant | 659,701 | Reporter |
| 2025-07-28 | NIH grant | 338,316 | Reporter |
Showing 5 of 95 events.
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Hennepin County Medical Center, Minneapolis | Co sponsors trial with | 1 |
| Gavin Bart | Co sponsors trial with | 1 |
| The Emmes Company, LLC | Co sponsors trial with | 1 |
| The Miriam Hospital | Co sponsors trial with | 1 |
| Denver Infectious Disease Consultants, PLLC | Co sponsors trial with | 1 |
Latest dated events (183)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-30 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-17 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-08-19 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-07-31 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 183 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| HENNEPIN HEALTHCARE RESEARCH INSTITUTE | Certificate of waiver | Active |
Biomarker capability evidence (78)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| ERVK-10 | Trial collaborator | Named in trial inclusion criteria |
| ERVK-18 | Trial collaborator | Named in trial inclusion criteria |
| ERVK-19 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 78 evidence rows.
Biomarkers this organization publishes on (82)
Shown in this order: most publications first.
Showing 5 of 82 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.